Literature DB >> 7365697

Acetaminophen toxicity in human lymphocytes in vitro.

S P Spielberg.   

Abstract

Studies of drug toxicity in humans are limited by the paucity of noninvasive approaches for assessing individual susceptibility to toxicity. An in vitro system for examining acetaminophen toxicity has been developed by using human lymphocytes and a mouse microsomal drug metabolizing system. Acetaminophen metabolites produced by the microsomes caused a dose-dependent depletion of lymphocyte glutathione content. No depletion was seen with heat-inactivated microsomes or in the absence of the metabolizing system. Toxicity to the lymphocytes was assayed by trypan blue dye exclusion, release of lactic dehydrogenase to the culture medium and loss of ability to respond to concanavalin A with [3H]thymidine incorporation into deoxyribonucleic acid. Toxicity was marked at concentrations of acetaminophen causing greater than 80% depletion of glutathione, similar to plasma concentrations associated with hepatotoxicity in vivo. The method may serve as a means of examining individual differences in cell defenses against electrophilic drug metabolite toxicity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7365697

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  23 in total

Review 1.  A paradigm for examining toxicant effects on viability, structure, and axonal transport of neurons in culture.

Authors:  D J Brat; S Brimijoin
Journal:  Mol Neurobiol       Date:  1992 Summer-Fall       Impact factor: 5.590

Review 2.  Idiosyncratic drug reactions: a mechanistic evaluation of risk factors.

Authors:  B K Park; M Pirmohamed; N R Kitteringham
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

3.  Manipulation of the N-alkyl substituent in amodiaquine to overcome the verapamil-sensitive chloroquine resistance component.

Authors:  S R Hawley; P G Bray; P M O'Neill; D J Naisbitt; B K Park; S A Ward
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 4.  In vitro testing for diagnosis of idiosyncratic adverse drug reactions: Implications for pathophysiology.

Authors:  Abdelbaset A Elzagallaai; Michael J Rieder
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

5.  Predictive value of the lymphocyte toxicity assay in the diagnosis of drug hypersensitivity syndrome.

Authors:  Abdelbaset A Elzagallaai; Zahra Jahedmotlagh; Blanca R Del Pozzo-Magaña; Sandra R Knowles; Asuri N Prasad; Neil H Shear; Michael J Rieder; Gideon Koren
Journal:  Mol Diagn Ther       Date:  2010-10-01       Impact factor: 4.074

6.  Bioactivation of dapsone to a cytotoxic metabolite: in vitro use of a novel two compartment system which contains human tissues.

Authors:  R J Riley; P Roberts; M D Coleman; N R Kitteringham; B K Park
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

7.  Metabolism of ciamexon by human liver microsomes: an investigation into the formation of stable, chemically reactive and cytotoxic metabolites.

Authors:  M D Tingle; B K Park
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

8.  Nitrofurantoin cytotoxicity. In vitro assessment of risk based on glutathione metabolism.

Authors:  S P Spielberg; G B Gordon
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

9.  Selective inhibition of acetaminophen oxidation and toxicity by cimetidine and other histamine H2-receptor antagonists in vivo and in vitro in the rat and in man.

Authors:  M C Mitchell; S Schenker; K V Speeg
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

10.  Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine.

Authors:  M Pirmohamed; A Graham; P Roberts; D Smith; D Chadwick; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.